Rheumatology Practices
Sell Your Rheumatology Practice to a Buyer Who Gets the Model
Rheumatology practices combine chronic autoimmune care with high-value biologic infusion revenue that most buyers don’t fully understand. We help you get a valuation that reflects that complexity, and find a buyer who will protect care continuity for your patients.
Market Snapshot
Biologic Therapy Reshapes a High-Demand Specialty
Rheumatology practice sales don’t follow the same playbook as other specialties. A few things make this market distinct.
Demand Is Outpacing Supply
A national shortage of rheumatologists, combined with rising diagnosis rates for autoimmune conditions, has made well-established practices highly sought-after acquisition targets.
In-Office Infusion Is a Major Value Driver
Practices administering biologic infusions for conditions like rheumatoid arthritis and lupus generate a distinct, higher-margin revenue stream that buyers actively look for.
Prior Authorization Burden Shapes Buyer Interest
Biologic therapies carry heavy prior-authorization requirements, and buyers evaluate how efficiently a practice manages that process alongside its clinical volume.
Valuation
Three Things That Move Rheumatology Practice Value
Infusion & Biologic Revenue
In-office infusion suites for biologic therapies add durable, higher-margin revenue that’s harder for a buyer to replicate.
Payer Mix & Prior Authorization Efficiency
A healthy payer mix and streamlined prior-authorization workflows give buyers a clearer picture of collectible, predictable revenue.
Ancillary Diagnostic Capabilities
Musculoskeletal ultrasound and in-house bone density (DEXA) scanning add revenue streams buyers weigh alongside standard visit billing.
Buyer Landscape
Understanding Your Buyer Pool
Because infusion capacity and referral relationships carry real weight in rheumatology, we help you understand not just what each buyer will pay, but how they tend to run a practice — and support its patients — after close.
| Buyer Type | What They're Looking For |
|---|---|
| Multi-specialty groups & health systems | Practices that strengthen autoimmune and musculoskeletal service lines and referral networks within their existing footprint. |
| Private equity–backed platforms | Multi-provider practices with strong infusion revenue, diagnostic capabilities, and room to add locations or providers. |
| Individual rheumatologists | Solo or small practices, often prioritizing patient continuity and clinical culture as much as price. |
Our Process
How We Approach a Rheumatology Practice Sale
01
Confidential Consultation
Understanding your patient panel, ancillary services, and what continuity means to you.
02
Specialty Valuation
Accounting for infusion/biologic revenue, payer mix, and diagnostic capabilities.
03
Confidential Marketing
Preparing a confidential executive summary and readying your practice for the market.
04
Buyer Vetting & Offers
Introducing vetted buyers and evaluating how each plans to support your patients and clinical team.
05
Negotiation & Diligence
Navigating diligence, including infusion suite compliance, specialty drug billing, and payer contracts.
06
The Handoff
A transition plan built to keep patients, providers, and referral sources intact.
Proof
Our Track Record
85%
of engagements reach close
80+
combined years of healthcare-specific brokerage experience
95%
of clients land within 10% of expected valuation
FAQ
Common Questions
Will my patients keep seeing the same providers after a sale?
In most transitions, yes — buyers acquiring a rheumatology practice are typically buying the physician team along with the patient panel, since continuity is critical for patients managing chronic autoimmune conditions. We prioritize buyers who plan to retain your providers, and we build retention terms into the deal structure wherever possible.
How does my in-office infusion program affect my valuation?
An established biologic infusion program is typically viewed as a higher-margin, more durable revenue stream than standard visit billing alone, and buyers actively seek out practices with this capability. We help you document your infusion volume, payer mix, and margins clearly so buyers price it as the distinct asset it is.
How does the prior authorization burden for biologics affect what my practice is worth?
Buyers pay close attention to how efficiently a practice manages prior authorizations, since delays or denials can directly affect collectible revenue on high-cost biologic therapies. We help you present your prior-authorization workflows and approval rates clearly, so buyers can see the operational strength behind your revenue rather than discounting for perceived administrative risk.